Collagen supplements have been studied for years as a way to support joint comfort in osteoarthritis (OA), but how strong is the evidence really? Two meta-analyses published in 2024 add weight to the picture by pooling results from multiple randomized controlled trials (RCTs) — the type of study considered most reliable for testing whether a treatment works.

What the research looked at

The first analysis, a trial-sequential meta-analysis published in the journal Osteoarthritis and Cartilage, pooled randomized controlled trials testing collagen derivatives for osteoarthritis pain. Trial-sequential analysis is a statistical method that checks whether enough evidence has accumulated across trials to draw a reliable conclusion, rather than relying on a single study. Separately, a 2024 updated systematic review and meta-analysis looked specifically at knee osteoarthritis, combining data from 11 randomized controlled trials involving roughly 870 participants who took hydrolyzed collagen.

What it found

The trial-sequential meta-analysis found that collagen derivatives significantly reduced osteoarthritis pain compared with control groups. Importantly, when the researchers restricted their analysis to only the studies judged to have a low risk of bias — meaning the most methodologically sound trials — pain scores remained significantly lower with collagen than with control, with a standardized mean difference of about -0.30. This suggests the pain-reducing effect held up even under stricter scrutiny.

The second analysis, focused on knee osteoarthritis, found that hydrolyzed collagen improved mobility and reduced pain severity across the pooled trials. Across both bodies of research, collagen was generally well tolerated by participants.

What it means (and the limits)

Together, these two 2024 analyses strengthen the case that collagen derivatives — including hydrolyzed collagen — can meaningfully reduce osteoarthritis pain and support mobility, with a reasonable safety profile. A standardized mean difference of around -0.30 reflects a modest-to-moderate effect, not a dramatic one, and it describes average outcomes across groups of people, not what any one individual will experience.

It's important to be clear about what this evidence does and doesn't show. Collagen supplements are not a cure for osteoarthritis, and they do not reverse joint damage. Their effects on pain and mobility tend to build gradually with consistent use, rather than working immediately. As with any meta-analysis, results depend on the quality and design of the underlying trials, and even after restricting to low-risk-of-bias studies, questions remain about optimal dose, duration, and which patients benefit most. People considering collagen supplementation for joint health should view it as one supportive option among others, and should talk to their doctor or pharmacist about whether it fits their overall care plan.

Sources: https://pubmed.ncbi.nlm.nih.gov/38218227/ · https://www.oarsijournal.com/article/S1063-4584(24)00004-9/fulltext

Dual-action joint collagen

Mafsal Riyadi combines the two collagen types most studied for joints — high-tripeptide hydrolyzed collagen and undenatured type II collagen — in one licensed dietary supplement (EDA reg. no. 14711/2026). Research about ingredient categories is general and is not a claim about any individual product.

Learn about Mafsal Riyadi

This is a plain-language summary of published research for general education. It is not medical advice, a diagnosis, or a treatment recommendation, and individual studies have limitations. Dietary supplements are not intended to diagnose, treat, cure, or prevent any disease. Consult your doctor or pharmacist about your own situation.